Trial Profile

A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2020 According to a Takeda China media release, ADCETRIS (brentuximab vedotin) has been officially approved by Chinas National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) or CD30-positive Hodgkin Lymphoma. The local approval of ADCETRIS in China is based on the data from clinical studies SG035-0004, SG035-0003 and C25007.
13 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
29 Jan 2018 Results (n=380) of pooled data from six trials assessing population pk and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in ctcl patients, were published in the Clinical Pharmacology and Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com